New drug shows promise against rare salivary gland cancer
NCT ID NCT03781986
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study tests a new drug called APG-115, alone or with chemotherapy, in people with a certain type of salivary gland cancer that has a normal p53 gene. The goal is to see if the drug can shrink tumors and to find the best dose with acceptable side effects. About 41 adults with advanced cancer that cannot be cured will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SALIVARY GLAND CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Sharper radiation boost aims to tackle head and neck cancers that return
- Radiation's hidden toll: study tracks tooth loss in cancer survivors
- New pill-chemo combo takes on hard-to-treat cancers
- New drug hope for rare salivary gland cancer
- Promising drug combo targets Hard-to-Treat salivary cancer